Showing results (321-330 of 333) with videos related to
Sort By:
Pageof 34
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2023
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 TrialKoichi Goto, Yasushi Goto, Toshio Kubo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2024
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 StudyMyung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares, et al.Molecular Oncology|October 21, 2023
NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT studySatoshi Ikeda, Masahiro Tsuboi, Kazuko Sakai, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2026
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)Aaron C Tan, Bin-Chi Liao, Molly Li, et al.European Journal of Cancer (Oxford, England : 1990)|January 24, 2021
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort studyKentaro Ito, Takeharu Yamanaka, Hidetoshi Hayashi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2023
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket StudyYoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.Nature|January 22, 2025
Immune evasion through mitochondrial transfer in the tumour microenvironmentHideki Ikeda, Katsushige Kawase, Tatsuya Nishi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSASe-Hoon Lee, Shun Lu, Hidetoshi Hayashi, et al.Targeted Oncology|November 3, 2025
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON StudyRachel E Sanborn, Caicun Zhou, Ke-Jing Tang, et al.Pageof 34